These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 24136928

  • 1. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM.
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [Abstract] [Full Text] [Related]

  • 2. Phentermine/topiramate for the treatment of obesity.
    Smith SM, Meyer M, Trinkley KE.
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [Abstract] [Full Text] [Related]

  • 3. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [Abstract] [Full Text] [Related]

  • 4. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH.
    Am J Cardiol; 2013 Apr 15; 111(8):1131-8. PubMed ID: 23375187
    [Abstract] [Full Text] [Related]

  • 5. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.
    Am J Clin Nutr; 2012 Feb 15; 95(2):297-308. PubMed ID: 22158731
    [Abstract] [Full Text] [Related]

  • 6. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, Troupin B, Day WW.
    Diabetes Care; 2014 Apr 15; 37(4):912-21. PubMed ID: 24103901
    [Abstract] [Full Text] [Related]

  • 7. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.
    Lancet; 2011 Apr 16; 377(9774):1341-52. PubMed ID: 21481449
    [Abstract] [Full Text] [Related]

  • 8. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec 16; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 9. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN.
    Hormones (Athens); 2013 Dec 16; 12(4):507-16. PubMed ID: 24457398
    [Abstract] [Full Text] [Related]

  • 10. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW.
    Obesity (Silver Spring); 2012 Feb 16; 20(2):330-42. PubMed ID: 22051941
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH, Bowden CH, DiDonato KP, McCullough PA.
    Sleep; 2012 Nov 01; 35(11):1529-39. PubMed ID: 23115402
    [Abstract] [Full Text] [Related]

  • 12. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
    Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T.
    Int J Eat Disord; 2020 Feb 01; 53(2):266-277. PubMed ID: 31721257
    [Abstract] [Full Text] [Related]

  • 13. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW, McClendon KS, Riche DM.
    Ann Pharmacother; 2013 Feb 01; 47(7-8):1007-16. PubMed ID: 23800750
    [Abstract] [Full Text] [Related]

  • 14. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
    Guo F, Garvey WT.
    Diabetes Care; 2017 Jul 01; 40(7):856-862. PubMed ID: 28455281
    [Abstract] [Full Text] [Related]

  • 15. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
    Garvey WT.
    Expert Opin Drug Saf; 2013 Sep 01; 12(5):741-56. PubMed ID: 23738843
    [Abstract] [Full Text] [Related]

  • 16. Phentermine and topiramate extended release (Qsymia™): first global approval.
    Cameron F, Whiteside G, McKeage K.
    Drugs; 2012 Oct 22; 72(15):2033-42. PubMed ID: 23039320
    [Abstract] [Full Text] [Related]

  • 17. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.
    Obes Res; 2003 Jun 22; 11(6):722-33. PubMed ID: 12805393
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
    Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, Peterson C, Siegel R.
    Diabetes Obes Metab; 2020 Apr 22; 22(4):480-491. PubMed ID: 31696603
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Safety During and After Use of Phentermine and Topiramate.
    Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS.
    J Clin Endocrinol Metab; 2019 Feb 01; 104(2):513-522. PubMed ID: 30247575
    [Abstract] [Full Text] [Related]

  • 20. Tolerability and safety of the new anti-obesity medications.
    Hainer V, Aldhoon-Hainerová I.
    Drug Saf; 2014 Sep 01; 37(9):693-702. PubMed ID: 25096956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.